Telitacicept for active primary Sjögren's disease
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests an investigational drug called telitacicept for people with active primary Sjögren's disease. The goal is to see if it can reduce symptoms like joint pain, fatigue, and swelling better than a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with primary Sjögren's disease (not caused by another autoimmune condition).
- You have a positive blood test for anti-SSA (Ro) antibodies.
- Your disease is moderately to highly active (score of 5 or more on the ESSDAI scale).
- You do not have another autoimmune disease like lupus or rheumatoid arthritis that could better explain your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ICP-488 for people with primary Sjögren's syndrome (the main form, not caused by other conditions). The goal is to see if the drug can help control symptoms better than a placebo. Participants must have active disease and stable treatment.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This study tests an investigational drug called ESG206, which targets a protein on immune cells, to see if it can safely reduce symptoms of primary Sjögren's syndrome. It is for people whose Sjögren's is not caused by another disease and who have active symptoms.
This study tests a new pill called upadacitinib (a JAK inhibitor) for people with active Sjögren's syndrome. It may help reduce dryness, fatigue, and joint pain by calming the immune system.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
Hear when a new Primary Sjogren's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.